Therefore, it was shown that resistance to immunotherapy was overcome, as these patients, previously unresponsive to anti-PD-1 therapy, showed post-FMT clinical benefit, with tumor reduction and/or long-term disease stability. The gene discussed is RPL17; the disease is neoplasm.